Antithrombotic and profibrinolytic activities of eckol and dieckol

Journal of Cellular Biochemistry

Volumn 113, Issue 9, 2012, Pages 2877-2883

  Kim, Tae Hoon ^a   Ku, Sae Kwang ^a   Bae, Jong Sup ^b  

^a Daegu Haany University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

coagulation cascade; dieckol; Eckol; endothelium; fibrinolysis

Indexed keywords

ANTICOAGULANT AGENT; DIECKOL; ECKOL; HYDROXYL GROUP; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTHROMBIN TIME; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; BENZOFURANS; DIOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XA; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED ICR; PROTHROMBIN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA;

EISENIA BICYCLIS;

EID: 84863669047     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24163     Document Type: Article

References (25)

1. Bae JS, Rezaie AR,. 2008. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thromb Haemost 100: 101-109.
2. Davie EW,. 1995. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 74: 1-6.
3. Davie EW, Fujikawa K, Kisiel W,. 1991. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 30: 10363-10370.
4. Dejana E, Callioni A, Quintana A, de Gaetano G,. 1979. Bleeding time in laboratory animals. IIâ€"A comparison of different assay conditions in rats. Thromb Res 15: 191-197.
5. Della Valle P, Crippa L, Garlando AM, Pattarini E, Safa O, Vigano D'Angelo S, D'Angelo A,. 1999. Interference of lupus anticoagulants in prothrombin time assays: Implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome. Haematologica 84: 1065-1074.
6. Esmon CT,. 2001. Role of coagulation inhibitors in inflammation. Thromb Haemost 86: 51-56.
7. Furie B, Furie BC,. 2005. Thrombus formation in vivo. J Clin Invest 115: 3355-3362.
8. Ghosh S, Ezban M, Persson E, Pendurthi U, Hedner U, Rao LV,. 2007. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 5: 336-346.
9. Hamaguchi E, Takamura T, Shimizu A, Nagai Y,. 2003. Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther 307: 987-994.
10. Jung HA, Oh SH, Choi JS,. 2010. Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett 20: 3211-3215.
11. Li Y, Qian ZJ, Ryu B, Lee SH, Kim MM, Kim SK,. 2009. Chemical components and its antioxidant properties in vitro: An edible marine brown alga, Ecklonia cava. Bioorg Med Chem 17: 1963-1973.
12. Lien EJ, Ren S, Bui HH, Wang R,. 1999. Quantitative structure-activity relationship analysis of phenolic antioxidants. Free Radic Biol Med 26: 285-294.
13. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G,. 2000. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells. Atherosclerosis 152: 359-366.
14. Monroe DM, Hoffman M, Roberts HR,. 2002. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 22: 1381-1389.
15. Nagayama K, Iwamura Y, Shibata T, Hirayama I, Nakamura T,. 2002. Bactericidal activity of phlorotannins from the brown alga Ecklonia kurome. J Antimicrob Chemother 50: 889-893.
16. Nowak P, Zbikowska HM, Ponczek M, Kolodziejczyk J, Wachowicz B,. 2007. Different vulnerability of fibrinogen subunits to oxidative/nitrative modifications induced by peroxynitrite: Functional consequences. Thromb Res 121: 163-174.
17. Okada Y, Ishimaru A, Suzuki R, Okuyama T,. 2004. A new phloroglucinol derivative from the brown alga Eisenia bicyclis: Potential for the effective treatment of diabetic complications. J Nat Prod 67: 103-105.
18. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL,. 1994. Antithrombin: The principal inhibitor of thrombin. Semin Thromb Hemost 20: 353-372.
19. Olson ST, Bjork I,. 1994. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost 20: 373-409.
20. Philip-Joet F, Alessi MC, Philip-Joet C, Aillaud M, Barriere JR, Arnaud A, Juhan-Vague I,. 1995. Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 8: 1352-1356.
21. Quinn C, Hill J, Hassouna H,. 2000. A guide for diagnosis of patients with arterial and venous thrombosis. Clin Lab Sci 13: 229-238.
22. Rao LV, Rapaport SI, Lorenzi M,. 1988. Enhancement by human umbilical vein endothelial cells of factor Xa-catalyzed activation of factor VII. Blood 71: 791-796.
23. Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB,. 1995. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic Res 22: 375-383.
24. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Jr., Loskutoff DJ,. 1988. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263: 5797-5803.
25. Sugo T, Nakamikawa C, Tanabe S, Matsuda M,. 1995. Activation of prothrombin by factor Xa bound to the membrane surface of human umbilical vein endothelial cells: Its catalytic efficiency is similar to that of prothrombinase complex on platelets. J Biochem 117: 244-250.